Some companies with mRNA manufacturing capacity

Alnylam Pharmaceutics
Arcturus Therapeutics
Arrowhead Pharmaceuticals
BioNtech SE
CurVac NV
Dicerna Pharmaceuticals
Gritstone Bio.
Maravai LifeSciences Holdings
Marian Biotech
mRNA RiboTherapeutics, Inc.
Sorrento Therapeutics
Tekmira Pharmaceuticals Corporation
Translate Bio

Some random SEC filings.

Sorrento Therapeutics

mRNA RiboTherapeutics, Inc., Second Amendment to Patent Sublicense Agreement

Tekmira Pharmaceuticals Corporation

Arcturus Therapeutics Announces Second Quarter 2021 Financial Results and mRNA Vaccine and Therapeutics Pipeline Progress

Translate Bio Announces Closing of Collaboration and Licensing Agreement with Sanofi Pasteur to Develop mRNA Vaccines for Infectious Diseases

CureVac Streamlines European Network for mRNA Product Manufacturing

Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development

Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics

Marina Biotech

Novartis. CureVac and Novartis Sign Initial Agreement on Manufacturing of COVID-19 Vaccine Candidate, CVnCoV

Arcturus Therapeutics, Inc.


mRNA RiboTherapeutics, Inc. This Patent Sublicense Agreement (“Agreement”) is between mRNA RiboTherapeutics, Inc., a Wisconsin corporation having a place of business at 726 Post Road, Madison, WI 53713, USA (“mRNA RiboTherapeutics”) and BioNTech AG, a German corporation having its principal place of business at An der Goldgrube 12, 55131 Mainz, Germany (“Company”). This Agreement is effective as of July 14, 2017 (the “Effective Date“). Each of Company and mRNA RiboTherapeutics are referred to herein as a “Party” and collectively as the “Parties”.

Research Collaboration and License Agreement by and between Pfizer inc. and BioNTech RNA Pharmaceuticals gmbh and Biontech AG

Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals, February 22, 2021

Curevac AG and Genmab B.V. license.

Arcturus Therapeutics 2018 10-K.

Development and Option Agreement by and between CureVac AG and Arcturus Therapeutics Inc. dated 1 January 2018.

Misc company web pages: